Michael Levy
Neurology · Boston, MANPI 1184776510
Payments from drug & device makers
Across 485 payments — averaging $5942.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$916K
- AstraZeneca$826K
- Genentech, Inc.$619K
- Amgen$341K
- Hoffmann-la Roche Limited$28K
- Tanabe Pharma Corporation$28K
- plus $125K from 24 others
Across 24 payments — averaging $10,051 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$223K
- F. Hoffmann-la Roche AG$17K
- UCB, Inc.$1K
What the payments were for
- Consulting fees$222,05057%
- Speaking & faculty fees$66,41117%
- Travel & lodging$85,32122%
- Food & beverage$8,8312%
- Education$4,1781%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 43 | $915,814 |
| AstraZeneca(2 entities) | 152 | $825,562 |
| Genentech, Inc. | 37 | $618,593 |
| Amgen(2 entities) | 118 | $340,824 |
| Hoffmann-la Roche Limited | 6 | $28,338 |
| Tanabe Pharma Corporation | 12 | $28,104 |
| F. Hoffmann-la Roche AG | 16 | $25,419 |
| Genentech USA, Inc. | 27 | $23,372 |
| UCB GmbH | 8 | $20,360 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 14 | $10,553 |
| Biogen | 3 | $8,287 |
| Bristol Myers Squibb | 2 | $8,189 |
| E.r. Squibb & Sons, L.L.C. | 6 | $7,365 |
| Sanofi US Services Inc. | 8 | $6,617 |
| Chugai Pharmaceutical Co., Ltd. | 3 | $5,858 |
| Merck | 1 | $2,093 |
| Johnson & Johnson | 1 | $1,620 |
| Novartis Pharma AG | 1 | $1,491 |
| Ipsen Bioscience Inc. | 2 | $1,000 |
| Ipsen Pharma SAS | 1 | $630 |
| UCB, Inc. | 6 | $515 |
| AbbVie | 1 | $400 |
| Sanofi | 3 | $332 |
| TG Therapeutics, Inc. | 4 | $300 |
| Inari Medical, Inc. | 1 | $195 |
| EMD Serono, Inc. | 5 | $152 |
| Novartis | 1 | $82 |
| Longeviti Neuro Solutions Inc | 1 | $75 |
| Roche Products Limited | 1 | $32 |
| Bard Peripheral Vascular, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,882,185 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EnspryngSatralizumab-Mwge | 29 | $689,179 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 38 | $260,122 |
| FerriproxDeferiprone | 25 | $161,568 |
| Deferiprone | 29 | $154,487 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 11 | $150,360 |
| Ferriprox (3 Times A Day)Deferiprone | 21 | $128,150 |
| Teriflunomide | 12 | $42,404 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $13,007 |
| BelbucaBuprenorphine Hcl | 12 | $11,326 |
| Dimethyl Fumarate | 17 | $2,424 |
| Pregabalin | 41 | $1,838 |
| Gabapentin | 47 | $1,079 |
| Mycophenolic AcidMycophenolate Sodium | 20 | $652 |
| Duloxetine Hcl | 14 | $472 |
| Dalfampridine ErDalfampridine | 13 | $445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Enspryng | $23,372 | $689,17929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 761 neurology providers in Massachusetts.
Other neurology in Boston
- Stephanie RutrickBoston$31.4M
- Scott PlotkinBoston$26.3M
- Patrick WenBoston$18.2M
- James BerryBoston$8.9M
- Isabel Arrillaga-RomanyBoston$8.2M
- Mahmut GurolBoston$7.4M
- Gad MarshallBoston$6M
- Shawn MurphyBoston$5.9M
- Suma BabuBoston$5.8M
- Luis Gonzalez CastroBoston$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.